Skip to main content
Equibles
ABVC logo

ABVC · Abvc Biopharma, Inc. · Metrics

Track ABVC — free

Use ABVC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABVC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.00 -0.01 (-0.99%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“For the six months ended June 30, 2026, the Company reported net loss of $2,500,418. As of June 30, 2026, the Company's working capital deficit was $5,282,776. In addition, the Company had net cash outflows of $1,138,656 from operating activities for the six months ended June 30, 2026. These conditions give rise to substantial doubt as to whether the Company will be able to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$29.29M
Shares
26.65M
Volume · Oct 5 49.83K Avg daily vol (3M) 132.44K

ABVC metrics

58 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.01
Market cap
$29.29M

Price action

20 metrics
Price change (1W)
-10.6%
Price change (30D)
-4.7%
Price change (3M)
-43.9%
Price change (6M)
-7.3%
Price change (YTD)
-52.6%
Price change (1Y)
-66.6%
Trailing year
Price change (5Y)
—
52-week high
$3.29
52-week low
$0.71
Change from 52-week high
-69.3%
Change from 52-week low
+42.1%
Annualized volatility
85.9%
Annualized volatility (3M)
103.1%
Beta
1.7
RSI (14D)
46.9
Price vs SMA 50
+2.1%
Price vs SMA 200
-26.7%
Avg volume (3M)
132,443
Relative volume
0.8
Average dollar volume
$157,919

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
26.65M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.8
reciprocal yield 35.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-24.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
172.6×
reciprocal yield 0.6%
EV / revenue historical average (5Y)
172.6×
reciprocal yield 0.6%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-2,416.0%
Trailing 12 months
Net margin
-2,671.8%
Gross profit (TTM)
$797,916
Operating profit (TTM)
−$6.52M
Net income (TTM)
−$7.11M
Trailing 12 months
Diluted EPS (TTM)
$-0.29
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.44

Growth

11 metrics
Revenue growth YoY
+104.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+49.9%
Year over year · more shares
Revenue CAGR (3Y)
-32.7%
Revenue CAGR (5Y)
-9.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-69.1%
Return on assets
-36.6%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
−$9.36M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
-42.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$31,944
Total assets
$19.40M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$2.69M
Capital expenditures (TTM)
$119,692
R&D (TTM)
$114,755
SG&A (TTM)
$2.84M
Stock compensation (TTM)
$3.56M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
15
13F filer change QoQ
+1
Institutional ownership
4.1%

Short interest

3 metrics
Short interest
1.9%
Latest settlement · 3.8 days to cover
Days to cover
3.8d
Short-squeeze score
49 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1173313 CUSIP 00091F304 13F (30d) 1 filings 1 filers Visit website